2022
DOI: 10.20517/mtod.2021.19
|View full text |Cite
|
Sign up to set email alerts
|

Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system

Abstract: Nonalcoholic fatty liver disease (NAFLD) onset and its progression towards nonalcoholic steatohepatitis (NASH) features increased intestinal permeability and leaky gut, thereby favoring the escape of endotoxin [lipopolysaccharides (LPS)] from the gut to the liver. The aim of this study was to resemble the crosstalk between intestine and liver during NAFLD by using an in vitro model of co-culture system. Enterocytes (Caco-2) were seeded on Transwell filters (pore size: 0.4 μm) and cultured for 21 days to consti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 36 publications
(44 reference statements)
0
1
0
Order By: Relevance
“…To create disease models, monolayers were cultured in their respective media supplemented with either 0.2% ethanol, 0.3 mM (2 palmitic acid (PA): 1 oleic acid (OA)) or a combination of 10 µg/ml IL-1β, 10 µg/ml IL-6 and 10 µg/ml TNF-α for 24 hours. These treatments (applied to both the apical and basolateral chambers) have been previous used to stimulate alcoholic lover disease (ALD), 35 Metabolic associated fatty liver disease (MAFLD) 36 and inflammation bowel disease (IBD). 37–39 …”
Section: Methodsmentioning
confidence: 99%
“…To create disease models, monolayers were cultured in their respective media supplemented with either 0.2% ethanol, 0.3 mM (2 palmitic acid (PA): 1 oleic acid (OA)) or a combination of 10 µg/ml IL-1β, 10 µg/ml IL-6 and 10 µg/ml TNF-α for 24 hours. These treatments (applied to both the apical and basolateral chambers) have been previous used to stimulate alcoholic lover disease (ALD), 35 Metabolic associated fatty liver disease (MAFLD) 36 and inflammation bowel disease (IBD). 37–39 …”
Section: Methodsmentioning
confidence: 99%